Iran breaks German monopoly in type 2 diabetes drug

TEHRAN, Feb. 07 (MNA) – An Iranian pharmaceutical company produced a drug to treat type 2 diabetes which was exclusively confined to Germany.

Sales manager of Abidi Pharmaceutical Co. Reihaneh Rouhani, while pointing to the unveiling process of Sitagliptin with brand name Ziptin to treat type 2 diabetes, said Iran could break the monopoly of Ziptin drug already produced by a German Co.

She added that each German package of Ziptin was sold $77 on the market with no importing company in charge; however, the domestic drug is now sold for only $8.

Emphasizing that domestic production of Ziptin saves high foreign exchange for the country, Rouhani added that the Iranian drug will be produced by local experts based on the required amount in the country.



News Code 105878

Your Comment

You are replying to: .
  • 2 + 7 =